



19 May 2010

The Company Announcements Platform
ASX Ltd
Sydney NSW 2000

Press Release Phylogica Ltd (ASX: PYC)

Phylogica to Present at Rodman & Renshaw Global Healthcare Conference

Perth, Australia – 18 May 2010: Phylogica Ltd (ASX: PYC), a Perth-based drug discovery company, announces that Dr Paul Watt, Chief Executive Officer, presented a company update at the Rodman & Renshaw Global Healthcare Conference being held in London, UK.

The presentation will be webcast live and may be accessed under the investors section of the Company's website, www.phylogica.com. The presentation will also be available for replay.

For further information, please contact:

Dr Paul Watt
CEO
Tel: +61 8 9382 8888
Mobile: +61 417 986 005
paulw@phylogica.com

About Phylogica (www.phylogica.com)

Phylogica is a leading drug discovery company (ASX; PYC) that has developed proprietary peptide (Phylomer[®]) libraries derived from sequenced biodiverse bacterial genome from some of the world's most extreme environments, such as terrestrial and deep-sea volcanic vents and geysers. This biodiversity has yielded peptides with unique drug-like structures and Phylogica has extensive data to validate the high quality of hits against different target classes, in addition to n vivo proof of concept of drug candidates and potential administration by a number of means, including parenteral or intranasal delivery. Phylogica aims to achieve rapid cash sustainability from the provision of fee-for-service screening of its peptide libraries against third-party targets, but to retain down-stream value through milestone payments and royalties for any resulting product candidate.

PO Box 8207, Subiaco East, Western Australia 6008
Level 22 Allendale Square, 77 St Georges Tce, Perth, Western Australia 6000
Tel: +61 8 93828888 Fax: +61 8 93258088
www.phylogica.com
ABN 48 098 391 961